Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Aug;49(8):3000605211034656.
doi: 10.1177/03000605211034656.

Cytomegalovirus seroprevalence among blood donors: a systematic review and meta-analysis

Tiruneh Adane  1 , Solomon Getawa  1
Affiliations
Meta-Analysis

Cytomegalovirus seroprevalence among blood donors: a systematic review and meta-analysis

Tiruneh Adane et al. J Int Med Res. 2021 Aug.

Abstract

Background: Screening for cytomegalovirus (CMV)-specific antibodies is not routine in some settings. Thus, transfusion of blood products poses risks for susceptible individuals.

Objectives: To investigate the global pooled CMV seroprevalence among volunteer blood donors.

Methods: This systematic review and meta-analysis was performed according to PRISMA guidelines. The databases searched included Embase, Google Scholar, Medline, PubMed, Web of Science, and Cochrane Library. Data were extracted independently and analyzed using STATA version 11.

Results: The global seroprevalence of CMV IgG, CMV IgM, and both CMV IgM and IgG was 83.16% (95% confidence interval [CI]: 78.55-87.77%, I2 = 99.5%), 13.77% (95% CI: 11.59-15.95%, I2 = 98.8%), and 23.78% (95% CI: 10.50-37.06%, I2 = 98.7), respectively.

Conclusion: The global seroprevalence of CMV was high among blood donors. Therefore, regular CMV screening should be conducted to identify CMV-seronegative blood donors.

Keywords: Blood donor; cytomegalovirus; immunoglobulin G; immunoglobulin M; seroprevalence; systematic review.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interest: The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Flow chart of study selection for the systematic review and meta-analysis of the prevalence of anti-CMV antibodies among blood donors.
Figure 2.
Figure 2.
Forest plot of the prevalence of anti-CMV IgG among blood donors.
Figure 3.
Figure 3.
Forest plot of the prevalence of anti-CMV IgM among blood donors.
Figure 4.
Figure 4.
Estimated global CMV seroprevalence among blood donors.
Figure 5.
Figure 5.
Forest plot of the prevalence of anti-CMV IgM and IgG among blood donors.
Figure 6.
Figure 6.
Funnel plot of the prevalence of anti-CMV IgG among blood donors in the included studies.
Figure 7.
Figure 7.
Funnel plot of the prevalence of anti-CMV IgM among blood donors in the included studies.
See this image and copyright information in PMC

References

    1. Bawa MK, Mamman A, Olayinka A, et al.. Blood donor safety, prevalence and associated factors for cytomegalovirus infection among blood donors in Minna-Nigeria, 2014. Pan Afr Med J 2019; 32: 6. - PMC - PubMed
    1. Adjei A, Armah H, Narter-Olaga E.Seroprevalence of cytomegalovirus among some voluntary blood donors at the 37 military hospital, Accra, Ghana. Ghana Med J 2006; 40: 99–104. - PMC - PubMed
    1. Nogalski MT, Collins-McMillen D, Yurochko AD. Overview of human cytomegalovirus pathogenesis. Human Cytomegaloviruses. Springer, 2014, pp. 15–28. - PubMed
    1. Jobier A, Ali MA.Frequency rate of cytomegalovirus antibodies among blood donors in Khartoum state. African Journal of Medical Sciences 2018; 3(2).
    1. Ziemann M, Krueger S, Maier AB, et al.. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 2007; 47: 1972–1983. - PubMed